Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Total Current Liabilities (2018 - 2025)

Historic Total Current Liabilities for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to $4.0 million.

  • ImmunoTech's Total Current Liabilities fell 5997.03% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year decrease of 5997.03%. This contributed to the annual value of $9.5 million for FY2024, which is 1020.57% up from last year.
  • As of Q3 2025, ImmunoTech's Total Current Liabilities stood at $4.0 million, which was down 5997.03% from $10.4 million recorded in Q2 2025.
  • ImmunoTech's 5-year Total Current Liabilities high stood at $10.4 million for Q2 2025, and its period low was $2.9 million during Q2 2023.
  • Over the past 3 years, ImmunoTech's median Total Current Liabilities value was $9.2 million (recorded in 2024), while the average stood at $7.9 million.
  • As far as peak fluctuations go, ImmunoTech's Total Current Liabilities surged by 20648.18% in 2024, and later plummeted by 5997.03% in 2025.
  • Over the past 3 years, ImmunoTech's Total Current Liabilities (Quarter) stood at $8.7 million in 2023, then grew by 10.21% to $9.5 million in 2024, then crashed by 57.6% to $4.0 million in 2025.
  • Its Total Current Liabilities was $4.0 million in Q3 2025, compared to $10.4 million in Q2 2025 and $9.8 million in Q1 2025.